v3.26.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Total revenue $ 2,736.0 $ 2,645.5 $ 5,213.8 $ 5,076.5
Cost and expenses:        
Cost of sales, excluding amortization and impairment of acquired intangible assets 776.9 605.0 1,437.9 1,234.3
Research and development 529.6 399.0 1,068.6 833.1
Acquired in-process research and development, upfront and milestone expense 164.0 46.6 198.0 247.3
Selling, general and administrative 709.7 583.8 1,317.0 1,156.3
Amortization and impairment of acquired intangible assets 168.2 130.9 304.7 242.7
Collaboration profit sharing/(loss reimbursement) 68.8 75.0 143.0 133.1
(Gain) loss on fair value remeasurement of contingent consideration 2.5   23.0 22.8
Restructuring charges 165.4 (0.7) 173.3 34.6
Other (income) expense, net 18.5 48.7 38.2 117.1
Total cost and expense 2,603.6 1,901.5 4,703.7 4,021.3
Income before income tax (benefit) expense 132.4 744.0 510.1 1,055.2
Income tax (benefit) expense 34.9 109.2 93.1 179.9
Net income attributable to Biogen Inc. $ 97.5 $ 634.8 $ 417.0 $ 875.3
Net income per share:        
Basic earnings per share attributable to Biogen Inc. (in USD per share) $ 0.66 $ 4.33 $ 2.83 $ 5.98
Diluted earnings per share attributable to Biogen Inc. (in USD per share) $ 0.66 $ 4.33 $ 2.81 $ 5.97
Weighted-average shares used in calculating:        
Basic earnings per share attributable to Biogen Inc. (in USD per share) 147,700 146,500 147,400 146,300
Diluted earnings per share attributable to Biogen Inc. (in USD per share) 148,700 146,700 148,600 146,700
Product revenue, net        
Total revenue $ 1,916.4 $ 1,878.7 $ 3,668.7 $ 3,605.2
Revenue from anti-CD20 therapeutic programs        
Total revenue 513.5 467.3 932.6 845.5
Alzheimer's collaboration revenue        
Total revenue 63.7 54.9 123.2 87.9
Contract manufacturing, royalty and other revenue        
Total revenue $ 242.4 $ 244.6 $ 489.3 $ 537.9